- Marker Therapeutics has partnered with Cellipont Bioservices for cGMP manufacturing of MT-601, its lead MAR-T cell therapy.
- The agreement supports ongoing clinical development and positions the therapy for future commercial readiness.
Marker Therapeutics, a clinical-stage immuno-oncology company, has entered into a manufacturing agreement with Cellipont Bioservices, a US-based cell therapy CDMO, to support the production of MT-601, its lead Multi-Antigen Recognizing (MAR)-T cell therapy. The partnership will focus on cGMP manufacturing and scale-up for Marker’s ongoing Phase 1 APOLLO study.
MT-601 is currently being evaluated in patients with lymphoma who have either relapsed following anti-CD19 CAR-T therapy or are ineligible for such treatment. As previously reported by the company, 78% of the first nine patients showed an objective response, with four experiencing a complete response.
Under the new agreement, Cellipont will handle technology transfer and provide contract manufacturing services to support the continued clinical supply of MT-601. The collaboration is intended to facilitate the potential transition to pivotal trials and commercial production.
“This exciting collaboration with Cellipont is a critical step forward as we prepare for a potential pivotal trial,” said Dr. Juan Vera, President and CEO of Marker Therapeutics. He added that Cellipont’s capabilities are well suited to support the therapy through its next stages of development.
Cellipont operates a 76,000-square-foot facility in The Woodlands, Texas, and offers integrated CDMO services, including modular cleanrooms and advanced cell processing platforms. CEO Darren Head said, “We are proud to support Marker Therapeutics in advancing MT-601,” noting the therapy’s potential impact in addressing unmet needs in cancer care.
Stay ahead of trends and best practices
